Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary

Abstract

AKT-targeted therapy has value in a first-line setting as well as a second-line treatment for recurrent disease developing after platinum-based chemotherapy or bevacizumab treatment.